Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been assigned an average rating of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $92.60.

PBH has been the topic of a number of analyst reports. Canaccord Genuity Group boosted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, February 7th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday, January 24th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research report on Monday, December 9th. Finally, Oppenheimer boosted their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research report on Thursday, February 13th.

Institutional Trading of Prestige Consumer Healthcare

A number of large investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC boosted its stake in shares of Prestige Consumer Healthcare by 3.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock valued at $126,274,000 after purchasing an additional 49,331 shares during the period. Geode Capital Management LLC lifted its stake in Prestige Consumer Healthcare by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company’s stock worth $105,342,000 after acquiring an additional 21,951 shares during the period. Kayne Anderson Rudnick Investment Management LLC purchased a new stake in Prestige Consumer Healthcare in the fourth quarter worth about $84,932,000. Invesco Ltd. lifted its stake in Prestige Consumer Healthcare by 2.4% in the fourth quarter. Invesco Ltd. now owns 1,060,263 shares of the company’s stock worth $82,796,000 after acquiring an additional 24,392 shares during the period. Finally, Congress Asset Management Co. lifted its stake in Prestige Consumer Healthcare by 5.0% in the fourth quarter. Congress Asset Management Co. now owns 908,742 shares of the company’s stock worth $70,964,000 after acquiring an additional 43,619 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Trading Down 1.3 %

Shares of PBH opened at $86.26 on Friday. The company’s fifty day moving average is $79.67 and its 200 day moving average is $76.89. Prestige Consumer Healthcare has a fifty-two week low of $62.35 and a fifty-two week high of $88.36. The stock has a market capitalization of $4.27 billion, a PE ratio of 20.20, a P/E/G ratio of 2.69 and a beta of 0.50. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Sell-side analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.